Sign In
Buy ELPKF
Elopak Asa Earnings Calls
| Release date | Oct 29, 2025 |
| EPS estimate | $0.0821 |
| EPS actual | $0.0822 |
| EPS Surprise | 0.0487% |
| Revenue estimate | 311M |
| Revenue actual | 340.479M |
| Revenue Surprise | 9.48% |
| Release date | Aug 14, 2025 |
| EPS estimate | $0.0746 |
| EPS actual | $0.0406 |
| EPS Surprise | -45.58% |
| Revenue estimate | 310.702M |
| Revenue actual | 341.106M |
| Revenue Surprise | 9.79% |
| Release date | May 07, 2025 |
| EPS estimate | $0.0688 |
| EPS actual | $0.0690 |
| EPS Surprise | 0.291% |
| Revenue estimate | 303.633M |
| Revenue actual | 340.101M |
| Revenue Surprise | 12.01% |
| Release date | Feb 11, 2025 |
| EPS estimate | $0.0619 |
| EPS actual | $0.0322 |
| EPS Surprise | -47.92% |
| Revenue estimate | 298M |
| Revenue actual | 293.45M |
| Revenue Surprise | -1.53% |
Last 4 Quarters for Elopak Asa
Below you can see how ELPKF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 11, 2025 |
| Price on release | $2.81 |
| EPS estimate | $0.0619 |
| EPS actual | $0.0322 |
| EPS surprise | -47.92% |
| Date | Price |
|---|---|
| Feb 05, 2025 | $2.81 |
| Feb 06, 2025 | $2.81 |
| Feb 07, 2025 | $2.81 |
| Feb 10, 2025 | $2.81 |
| Feb 11, 2025 | $2.81 |
| Feb 12, 2025 | $2.81 |
| Feb 13, 2025 | $2.81 |
| Feb 14, 2025 | $2.81 |
| Feb 18, 2025 | $2.81 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
| Release date | May 07, 2025 |
| Price on release | $2.81 |
| EPS estimate | $0.0688 |
| EPS actual | $0.0690 |
| EPS surprise | 0.291% |
| Date | Price |
|---|---|
| May 01, 2025 | $2.81 |
| May 02, 2025 | $2.81 |
| May 05, 2025 | $2.81 |
| May 06, 2025 | $2.81 |
| May 07, 2025 | $2.81 |
| May 08, 2025 | $2.81 |
| May 09, 2025 | $2.81 |
| May 12, 2025 | $2.81 |
| May 13, 2025 | $2.81 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
| Release date | Aug 14, 2025 |
| Price on release | $2.81 |
| EPS estimate | $0.0746 |
| EPS actual | $0.0406 |
| EPS surprise | -45.58% |
| Date | Price |
|---|---|
| Aug 08, 2025 | $4.50 |
| Aug 11, 2025 | $2.81 |
| Aug 12, 2025 | $4.50 |
| Aug 13, 2025 | $2.81 |
| Aug 14, 2025 | $2.81 |
| Aug 15, 2025 | $4.50 |
| Aug 18, 2025 | $2.81 |
| Aug 19, 2025 | $2.81 |
| Aug 20, 2025 | $2.81 |
| 4 days before | -37.56% |
| 4 days after | 0% |
| On release day | 60.14% |
| Change in period | -37.56% |
| Release date | Oct 29, 2025 |
| Price on release | $2.81 |
| EPS estimate | $0.0821 |
| EPS actual | $0.0822 |
| EPS surprise | 0.0487% |
| Date | Price |
|---|---|
| Oct 23, 2025 | $2.81 |
| Oct 24, 2025 | $4.50 |
| Oct 27, 2025 | $2.81 |
| Oct 28, 2025 | $2.81 |
| Oct 29, 2025 | $2.81 |
| Oct 30, 2025 | $2.81 |
| Oct 31, 2025 | $4.50 |
| Nov 03, 2025 | $2.81 |
| Nov 04, 2025 | $2.81 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
Elopak Asa Earnings Call Transcript Summary of Q3 2025
Elopak reported its strongest quarter to date with record EBITDA (EUR 49m, ~17% margin) and very strong cash generation (operating cash flow EUR 55m). Organic revenue grew 1.2% in Q3 (about 2% YTD) with particularly strong performance in the Americas (USD-based growth ~18% on fixed currency) where the Little Rock plant turned profitable for the first time. Management announced an acceleration of capacity expansion in Little Rock with a third production line to be installed to capture additional customer wallet share and smaller-format demand (in production in 2027). EMEA showed resilience despite soft consumption; Pure-Pak volumes and market share gains offset weaker filling-machine mix. Currency (weaker USD vs EUR) was a headwind to reported revenue. Working capital improvements and continued operational leverage supported deleveraging (net debt reduced to EUR 272m and leverage ~2.1x, close to the midterm 2x target). Management reaffirmed midterm targets (4–6% organic growth, 15–17% EBITDA margin) and signalled pricing actions to offset expected raw material/board cost increases. Dividend payments continue (transitioning to two payments per year).
